拉米夫定治疗活动性肝炎肝硬化的疗效观察  

Curative effect of lamivudine on cirrhosis in patients with chronic active hepatitis B

作　　者：张美玲[1] 

机构地区：[1]中国石化第十建设公司职工医院,山东淄博255438

出　　处：《中国感染控制杂志》2004年第2期114-116,共3页Chinese Journal of Infection Control

摘　　要：目的　观察活动性肝炎肝硬化患者服用拉米夫定治疗的效果。方法　对 2 0 0 0年 2月～ 2 0 0 2年 2月某院门诊及住院治疗的 4 0例活动性肝炎肝硬化患者应用拉米夫定口服治疗 ,1 0 0mg/d ,连服 1 2个月。观察治疗前后的临床症状、体征 ,生化指标 ,病毒标记物改变情况。结果　 37例 (92 .5 0 % )患者治疗后病情稳定 ,生活质量改善 ,child pugh积分下降 ,肝功能恢复正常或好转 ,HBVDNA降至 <1 0 3 拷贝 /mL ,HBeAg阴转率达 2 9.73% (1 1 /37)。结论　乙型肝炎肝硬化患者伴有活动性病毒复制及肝炎时 ,应用拉米夫定治疗可改善肝功能 ,阻止病情进展 。Objective To study the curative effect of lamivudine on cirrhosis following chronic active hepatitis B. Methods Forty inpatients and outpatients in a hospital from February 2000 to February 2002 received lamivudine 100mg orally everyday for consecutive 12 months. Clinical symptoms, signs, biochemical exam results and viral markers were compared between before and after the treatment. Results After receiving lamivudine treatment, 37 patients' situation remained stable, life quality improved, child pugh score declined, and liver function became normal or better. The level of HBV DNA decreased to less than 10 3 copies/mL; HBeAg of 29.73% of patients (11/37) became negative. Conclusion Treatment with lamivudine for cirrhosis following chronic hepatitis B can improve liver function and life quality.

关 键 词：拉米夫定 治疗 活动性肝炎 肝硬化 乙型肝炎 

分 类 号：R512.6[医药卫生—内科学] R978.7[医药卫生—临床医学]